Fundz
Funding, M&A and exec moves matched to your market — guaranteed to pay for itself in a year, or we refund it. See terms for full details.See plans →

Enginprime Medical secures $12M in Series A financing, led by Qiming Venture Partners, to fund their China registration trial and support global clinical development.

PRIVATEAug 18, 2026•about 4 hours ago

Amount Raised

$12 Million

Round Type

Series A

ManufacturingBiotechnologyHealth CareMedicalMedical Device

Investors

Voyagers CapitalQiming Venture Partners

Description

Enginprime Medical has closed a $12M Series A financing round, led by Qiming Venture Partners. The funds will be used for the registration clinical trial of their product, OpusOne™, in China and to support its global clinical development. This financing is a significant step for Enginprime as they expand their percutaneous ventricular assist device technology. The company aims to deliver reliable and effective solutions for patients in need.

Company Information

Company

Enginprime Medical

About

Enginprime Medical is a developer of percutaneous ventricular assist device (pVAD) technology, established in 2023. The company is focused on developing next-generation pVAD systems, with its lead product, OpusOne™, designed to provide higher flow rates from a smaller catheter profile. Enginprime aims to advance clinical validation and support global commercialization of this innovative medical device. The company leverages engineering capabilities and advanced manufacturing methodologies for its offerings.

Don't miss Enginprime Medical's next move

Get an email the moment Enginprime Medical raises, hires an exec, or expands — usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Enginprime Medical's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.